KUALA LUMPUR, Dec 24 -- Invicro LLC, a Konica Minolta company, has appointed Dr Matthew Silva as its new Chief Executive Officer (CEO).
A statement said Dr Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately.
It is also mentioned in the same statement that co-founder of Invicro, Dr Jack Hoppin, will move on from his role as Invicro’s CEO to be the President of Konica Minolta Precision Medicine (KMPM). Dr Hoppin will remain on Invicro’s Board of Directors and will continue to serve on the KMPM Board.
In his new role, Dr Hoppin will work to synergise the companies under KMPM to help pharmaceutical sponsors and clinicians accelerate the development of targeted therapies via genetic and molecular profiling.
Meanwhile, Dr Silva will carry on Invicro’s strategic mission to support the drug discovery and development community. Invicro will continue to leverage its industry-leading imaging, chemistry and analysis expertise that span discovery through clinical research across multiple therapeutic areas.
With 20 years of diverse imaging experience, Dr Silva first joined Invicro in 2012 and most recently was EVP of Scientific Applications, where he led strategic efforts to expand the clinical oncology drug development and clinical trials.
Konica Minolta Inc acquired Invicro LLC and Ambry Genetics Corporation in September 2017 to accelerate its strategic vision to transform personalised medicine through the delivery of diagnostic services via genetics, imaging and digital pathology capabilities.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas.
More information at www.invicro.com.
-- BERNAMA
No comments:
Post a Comment